menu

New Opportunities to Manage Aortic Stenosis with TAVR

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

New Opportunities to Manage Aortic Stenosis with TAVR

close
0.50 credits
30 minutes
New Opportunities to Manage Aortic Stenosis with TAVR
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    The FDA has approved an expanded indication for several transcatheter heart valves that now includes patients with severe aortic valve stenosis with low surgical risk, and guidelines have been revised with updated recommendations. The focus of this activity includes use of echocardiographic and CT imaging to assess and refer patients earlier when aortic valve disease is suspected. The choice between TAVR and SAVR is examined, and faculty review transcatheter bioprosthetic failure and durability. Challenges discussed include patients who meet the standard criteria for severe aortic stenosis but are convinced that they have no symptoms.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Jay S. Giri, MD, MPH
    Assistant Professor of Medicine
    Director, Peripheral Intervention
    University of Pennsylvania
    Philadelphia, PA 

    Consulting Fees: AstraZeneca, Boston Scientific, Inari Medical
    No conflicts of interest reported.

    Renuka Jain, MD
    Director, Structural and Interventional Echocardiography
    Clinical Adjunct Associate Professor of Medicine
    Aurora St. Luke’s Medical Center
    Milwaukee, WI

    No conflicts of interest reported.

    Reviewers/Content Planners/Authors:

    • Ben Caref, PhD, has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Milly Marte has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Realize the importance of and develop greater competency for diagnosing and risk stratifying aortic stenosis disease
    • Describe the role and advantages of medical, SAVR, and TAVR therapeutic options based on evidence and guideline recommendations
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, IMCs, and other health care professionals who identify and treat patients with aortic stenosis.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Medtronic.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    The FDA has approved an expanded indication for several transcatheter heart valves that now includes patients with severe aortic valve stenosis with low surgical risk, and guidelines have been revised with updated recommendations. The focus of this activity includes use of echocardiographic and CT imaging to assess and refer patients earlier when aortic valve disease is suspected. The choice between TAVR and SAVR is examined, and faculty review transcatheter bioprosthetic failure and durability. Challenges discussed include patients who meet the standard criteria for severe aortic stenosis but are convinced that they have no symptoms.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Jay S. Giri, MD, MPH
    Assistant Professor of Medicine
    Director, Peripheral Intervention
    University of Pennsylvania
    Philadelphia, PA 

    Consulting Fees: AstraZeneca, Boston Scientific, Inari Medical
    No conflicts of interest reported.

    Renuka Jain, MD
    Director, Structural and Interventional Echocardiography
    Clinical Adjunct Associate Professor of Medicine
    Aurora St. Luke’s Medical Center
    Milwaukee, WI

    No conflicts of interest reported.

    Reviewers/Content Planners/Authors:

    • Ben Caref, PhD, has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Milly Marte has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Realize the importance of and develop greater competency for diagnosing and risk stratifying aortic stenosis disease
    • Describe the role and advantages of medical, SAVR, and TAVR therapeutic options based on evidence and guideline recommendations
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, IMCs, and other health care professionals who identify and treat patients with aortic stenosis.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Medtronic.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 7/24/21